Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3635-3644

  Tang, Ning ^a   Guo, Jun ^b   Zhang, Qianqian ^a   Wang, Yali ^b   Wang, Zhehai ^b  

^a UNIVERSITY OF JINAN   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Brain metastases; Chemotherapy; Epidermal growth factor receptor; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; GEMCITABINE; PACLITAXEL; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; WILD TYPE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW UP; GENETICS; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PACLITAXEL; PEMETREXED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84962224315     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6184     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90. doi:10.3322/caac.20107.
2. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007; 12:884-98. doi:10.1634/theoncologist.12-7-884.
3. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005; 23: 6207-19. doi:10.1200/jco.2005.03.145.
4. Huang Q, Ouyang X. Predictive biochemical-markers for the development of brain metastases from lung cancer: clinical evidence and future directions. Cancer Epidemiol. 2013; 37:703-7. doi:10.1016/j.canep.2013.06.003.
5. Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, Xu W, Sahgal A. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012; 4: Cd003869. doi:10.1002/14651858.CD003869.pub3.
6. Kondziolka D, Shin SM, Brunswick A, Kim I, Silverman JS. The biology of radiosurgery and its clinical applications for brain tumors. Neuro Oncol. 2015; 17:29-44. doi:10.1093/neuonc/nou284.
7. Ma L, Nichol A, Hossain S, Wang B, Petti P, Vellani R, Higby C, Ahmad S, Barani I, Shrieve DC, Larson DA, Sahgal A. Variable dose interplay effects across radiosurgical apparatus in treating multiple brain metastases. Int J Comput Assist Radiol Surg. 2014. doi:10.1007/s11548-014-1001-4.
8. Chang WS, Kim HY, Chang JW, Park YG, Chang JH. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? J Neurosurg. 2010; 113:73-8.
9. D'Ambrosio AL, DeYoung C, Isaacson SR. Radiosurgical management of brain metastases. Neurosurg Clin N Am. 2011; 22:45-51, vi. doi:10.1016/j.nec.2010.08.002.
10. Gaspar LE, Mehta MP, Patchell RA, Burri SH, Robinson PD, Morris RE, Ammirati M, Andrews DW, Asher AL, Cobbs CS, Kondziolka D, Linskey ME, Loeffler JS, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010; 96:17-32. doi:10.1007/s11060-009-0060-9.
11. Arrieta O, Villarreal-Garza C, Zamora J, Blake-Cerda M, de la Mata MD, Zavala DG, Muniz-Hernandez S, de la Garza J. Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011; 6:166. doi:10.1186/1748-717x-6-166.
12. Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer. 2010; 68:264-8. doi:10.1016/j.lungcan.2009.06.018.
13. Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. 2012; 118:3743-8. doi:10.1002/cncr.26709.
14. Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther. 2005; 315:222-9. doi:10.1124/jpet.105.090043.
15. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009; 27:5255-61. doi:10.1200/jco.2009.22.0616.
16. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med. 2006; 355:2542-50. doi:10.1056/NEJMoa061884.
17. Sgambato A, Casaluce F, Maione P, Rossi A, Ciardiello F, Gridelli C. Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown? J Thorac Dis. 2014; 6:578-80. doi:10.3978/j.issn.2072-1439.2014.06.14.
18. Fidler IJ. Antivascular therapy of cancer metastasis. J Surg Oncol. 2006; 94:178-80. doi:10.1002/jso.20380.
19. Gordon MS, Margolin K, Talpaz M, Sledge GW, Jr., Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001; 19:843-50.
20. Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012; 8:232-43. doi:10.1111/j.1743-7563.2012.01518.x.
21. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011; 29:2866-74. doi:10.1200/jco.2010.33.4235.
22. Lee YJ, Park IK, Park MS, Choi HJ, Cho BC, Chung KY, Kim SK, Chang J, Moon JW, Kim H, Choi SH, Kim JH. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. J Cancer Res Clin Oncol. 2009; 135:1647-54. doi:10.1007/s00432-009-0611-7.
23. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11:121-8. doi:10.1016/s1470-2045(09)70364-x.
24. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Seto T, Satouchi M, Tada H, Hirashima T, Asami K. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). J Clin Oncol: Amer Soc Clin Oncol 2012; 30.
25. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12:735-42. doi:10.1016/s1470-2045(11)70184-x.
26. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez J. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13:239-46.
27. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of oncology. 2012:mds214.
28. Sequist LV, Yang JC-H, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai C-M, Boyer M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology. 2013; 31:3327-34.
29. Wu Y-L, Zhou C, Hu C-P, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. The lancet oncology. 2014; 15:213-22.
30. Yang JC-H, Wu Y-L, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu C-P, O'Byrne K, Feng J. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology. 2015; 16:141-51.
31. Fokas E, Steinbach JP, Rödel C. Biology of brain metastases and novel targeted therapies: Time to translate the research. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2013; 1835:61-75.
32. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nature medicine. 2010; 16:116-22.
33. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2007; 25:5165-5171.
34. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004; 22:2184-91. doi:10.1200/jco.2004.11.022.
35. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev. 2000; 26:449-62. doi:10.1053/ctrv.2000.0194.
36. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, et al. LY231514, a pyrrolo [2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57:1116-23.
37. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul. 1998; 38:135-52.
38. Adjei AA. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol. 2000; 11:1335-41.
39. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013; 31:895-902. doi:10.1200/jco.2011.40.1174.
40. Lind JS, Lagerwaard FJ, Smit EF, Senan S. Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 74:1391-6. doi:10.1016/j.ijrobp.2008.10.026.
41. Kim JE, Lee DH, Choi Y, Yoon DH, Kim SW, Suh C, Lee JS. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009; 65:351-4. doi:10.1016/j.lungcan.2008.12.011.
42. Mok T, Yang JJ, Lam KC. Treating patients with EGFRsensitizing mutations: first line or second line-is there a difference? J Clin Oncol. 2013; 31:1081-8. doi:10.1200/jco.2012.43.0652.